Zie ook literatuurlijst van voeding, niet-toxische middelen en weinig belastende behandelingen specifiek bij blaaskanker van arts-bioloog drs. Engelbert Valstar.  

7 augustus 2022: Zie ook dit artikel: https://kanker-actueel.nl/biomarker-ercc1-voorspelt-overlevingskansen-voor-blaaskanker-en-of-chemo-vooraf-aan-operatie-cystectomie-nodig-is.html

7 augustus 2022: Bron: Front. Surg., 28 September 2021 Sec. Genitourinary Surgery

In dit artikel een reviewstudie over biomarkers bij  niet-spierinvasieve blaaskanker. De onderzoekers hebben een samenvatting gemaakt van 6 door de Amerikaanse Food and Drug Administration (FDA) goedgekeurde eiwit biomarkers, samen met nieuwe testen die gebruikmaken van genetische markers, epigenetische markers en exosomale markers. Zij bespreken de kracht van de bewijzen van de belangrijkste beschikbare testen. 

De FDA heeft momenteel 6 urinetests goedgekeurd om naast cystoscopie te gebruiken voor diagnose en toezicht bij niet-spier-invasieve blaaskanker. Deze omvatten BTA stat (Polymedco), BTA TRAK (Polymedco), NMP22 enzyme-linked immune-sorbent assay (ELISA) (Matritech), NMP22 BladderChek Test (Alere), uCyt (Scimedx) en UroVysion (Abbott Molecular). Deze testen kijken naar heel veel specifieke biomarkers, waaronder dus genetische markers, epigenetische markers en exosomale markers uit urinemonsters gehaald en zeer snel beschikbaar.

Het artikel is zo uitgebreid dat u beter naar het artikel zelf kunt gaan voor de beschrijvingen en de belangrijkste studies.

Klik op de titel van het abstract en bekijk ook de referentielijst daaronder:

REVIEW article

Front. Surg., 28 September 2021
Sec. Genitourinary Surgery
https://doi.org/10.3389/fsurg.2021.735868
This article is part of the Research Topic

Recent Advances in Bladder Cancer Diagnosis and Treatment

Biomarkers in Bladder Cancer Surveillance

Sukumar S. Sugeeta1Anand Sharma1Kenrick Ng1Arvind Nayak2 and Nikhil Vasdev2,3*
  • 1Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom
  • 2Department of Urology and Surgery, Lister Hospital, East and North Herts NHS Trust, Stevenage, United Kingdom
  • 3School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom

Aim: This is a narrative review with an aim to summarise and describe urinary biomarkers in the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a summary of FDA-approved protein biomarkers along with emerging ones which utilise genetic, epigenetic and exosomal markers. We discuss the current limitations of the available assays.

Background: Current guidelines advice a combination of cystoscopy, imaging,and urine cytology in diagnosis and surveillance. Although cytology has a high specificity, it is limited by low sensitivity particularly in low grade tumours. There are six FDA-approved urinary assays for diagnosis and surveillance of bladder cancer. They have shown to improve sensitivity and specificity to be used alongside cytology and cystoscopy but have a lower specificity in comparison to cytology and false positives often occur in benign conditions. Recent developments in laboratory techniques has allowed for use of markers which are RNA-, DNA-based as well as extracellular vesicles in the past decade.

Methods: Using the PubMed/Medline search engines as well as Google Scholar, we performed an online search using the terms “bladder cancer,” “non-muscle invasive bladder cancer,” and “urine biomarkers” with filter for articles in English published up to May 2021. Systematic reviews and original data of clinical trials or observational studies which contributed to the development of the biomarkers were collated.

Results: Biomarkers identified were divided into FDA-approved molecular biomarkers, protein biomarkers and gene-related biomarker with a table summarising the findings of each marker with the most relevant studies. The studies conducted were mainly retrospective. Due to the early stages of development, only a few prospective studies have been done for more recently developed biomarkers and limited meta-analyses are available.Therefore a detailed evaluation of these markers are still required to decide on their clinical use.

Conclusion: Advancements of analytical methods in BC has driven the research towards non-invasive liquid-based biomarkers in adjunct to urine cytology. Further large prospective studies are required to determine its feasibility in a clinical setting as they are not effective when used in isolation as they have their limitation. With the ongoing pandemic, other than reduction in costs and increased accuracy, the need for biomarkers to cope with delay in cystoscopies in diagnosis and surveillance is crucial. Thus clinical trials with direct comparison is required to improve patient care.


Conclusion

This paper has highlighted the various biomarkers in urothelial cancer and their significance in early diagnosis of bladder cancer. Whilst it's important to have biomarkers in NMIBC, differences in sensitivity and specificity limits their use in the community. These biomarkers have a significant role in future diagnosis of bladder cancer, and future studies will guide clinicians in using the most appropriate marker for screening. The advancement in analytical methods in BC has driven the research towards non-invasive liquid-based biomarkers in adjunct to urine cytology. This paper provides evidence that a second modality of screening tool may be beneficial to use in the diagnostic algorithm for bladder cancer. Studies identifying its feasibility in a clinical enviroment is important as they have limitations when used in isolation. Given this is a narrative review, further evaluation of these promising markers is required in more depth in terms of a meta-analysis along with the development of prospective studies in a surveillance setting. Meta-analyses on the newer markers have not been conducted as there is variability in patient cohorts utilised and more studies need to be conducted to obtain sufficient data. In addition to this, majority of studies are in a restrospective setting and prospective studies need to be developed to be able to further evaluate their clinical feasibility.

The ongoing pandemic has further accentuated the increasing need and relevance for biomarkers to cope with delay in cystoscopies in both diagnosis and surveillance. The use of more sensitive methods to detect true tumour recurrences could also play a role in assessment of the diagnostic accuracy of these markers, potentially reducing the number of cystoscopies for test-negative cases and introducing methods like blue light cystoscopy for test-positive cases. Further large, prospective clinical trials incorporating these biomarkers and usage of newer analytical methods in screening for high-risk patients and also in disease recurrence in will allow for its use in a clinical setting.

Author Contributions

SS collated and summarised studies to write up majority of this review. KN and AN were involved in editing. AS and NV contributed to the introduction and conclusion. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. (2019) 38:1895–904. doi: 10.1007/s00345-019-02984-4

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, Van Andel G, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus calmette-guérin. Eur Urol. (2016) 69:60–9. doi: 10.1016/j.eururo.2015.06.045

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Reid MD, Osunkoya AO, Siddiqui MT, Looney SW. Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol. (2012) 5:882–91.

PubMed Abstract | Google Scholar

4. Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, et al. Efficacy and safety of blue light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: a phase III, comparative, multicenter study. J Urol. (2018) 199:1158–65. doi: 10.1016/j.juro.2017.11.096

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Benderska-Söder N, Hovanec J, Pesch B, Goebel PJ, Roghmann F, Noldus J, et al. Toward noninvasive follow-up of low-risk bladder cancer - rationale and concept of the urofollow trial. Urol Oncol. (2020) 38: 886–95. doi: 10.1016/j.urolonc.2020.01.006

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. Ann Intern Med. (2015) 163:922–31. doi: 10.7326/M15-0997

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Wang Z, Que H, Suo C, Han Z, Tao J, Huang Z, et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis. Oncotarget. (2017) 8:100648–56. doi: 10.18632/oncotarget.22065

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Guo A, Wang X, Gao L, Shi J, Sun C, Wan Z. Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: a meta-analysis. Can Urol Assoc J. (2014) 8:E347–52. doi: 10.5489/cuaj.1668

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Sarosdy MF, Hudson MLA, Ellis WJ, Soloway MS, White Rd, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the bard bta stat test. Urology. (1997) 50:349–53. doi: 10.1016/S0090-4295(97)00292-6

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Pode DOV, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I, et al. TEST. J Urol. (1999) 161:443–6. doi: 10.1016/S0022-5347(01)61918-9

CrossRef Full Text | Google Scholar

11. Heicappell R, Schostak M, Müller M, Miller K. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand J Clin Lab Invest. (2000) 60:275–82. doi: 10.1080/003655100750046431

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Raitanen MP. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol. (2008) 26:45–50. doi: 10.1007/s00345-007-0230-3

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Thomas L, Leyh H, Marberger M. Multicenter trial of the quantitative bta trak assay in the detection of bladder cancer. Clin Chem. (2021) 45:472–7.

PubMed Abstract | Google Scholar

14. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol. (2003) 169:1975–82. doi: 10.1097/01.ju.0000067461.30468.6d

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. (1999) 162:53–7. doi: 10.1097/00005392-199907000-00014

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP III, et al. Bladder tumor markers beyond cytology: international consensus panel on bladder tumor markers. Urology. (2005) 66(Suppl 1):35–63. doi: 10.1016/j.urology.2005.08.064

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urolo Oncol. (2008) 26:646–51. doi: 10.1016/j.urolonc.2007.06.002

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. (2013) 121:591–7. doi: 10.1002/cncy.21327

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn. (2000) 2:116–23. doi: 10.1016/S1525-1578(10)60625-3

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. (2007) 127:295–301. doi: 10.1309/ADJL7E810U1H42BJ

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Savic S, Zlobec I, Thalmann GN, Engeler D, Schmauss M, Lehmann K, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer. (2009) 124:2899–904. doi: 10.1002/ijc.24258

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Comploj E, Mian C, Ambrosini-Spaltro A, Dechet C, Palermo S, Trenti E, et al. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses. Cancer Cytopathol. (2013) 121:392–7. doi: 10.1002/cncy.21287

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Sullivan PS, Nooraie F, Sanchez H, Hirschowitz S, Levin M, Rao PN, et al. Comparison of immunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma cancer. Cytopathology. (2021) 117:167–73. doi: 10.1002/cncy.20026

PubMed Abstract | CrossRef Full Text | Google Scholar

24. He H, Han C, Hao L, Zang G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. Oncol Lett. (2016) 12:83–8. doi: 10.3892/ol.2016.4556

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Todenhöfer T, Hennenlotter J, Tews V, Gakis G, Aufderklamm S, Kuehs U, et al. Impact of different grades of microscopic hematuria on the performance of urine-based markers for the detection of urothelial carcinoma. Urol Oncol. (2013) 31:1148–54. doi: 10.1016/j.urolonc.2011.10.011

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Ecke TH, Weiß S, Stephan C, Hallmann S, Arndt C, Barski D, et al. UBC® Rapid Test. A Urinary Point-of-Care (POC) assay for diagnosis of bladder cancer with a focus on non-muscle invasive high-grade tumors: results of a multicenter-study. Int J Mol Sci. (2018) 19:3841. doi: 10.3390/ijms19123841

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Lu P, Cui J, Chen K, Zhang J, Tao J, Han Z, et al. Diagnostic accuracy of the UBC® Rapid Test for bladder cancer: a meta-analysis. Oncol Lett. (2021) 16:3770–8. doi: 10.3892/ol.2018.9089

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, et al. Evaluation of a New Surviving ELISA and UBC® rapid for the detection of bladder cancer in urine. Int J Mol Sci. (2018) 19:226. doi: 10.3390/ijms19010226

PubMed Abstract | CrossRef Full Text | Google Scholar

29. D'Costa JJ, Goldsmith JC, Wilson JS, Bryan RT, Ward DG. A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder Cancer. (2016) 2:301–17. doi: 10.3233/BLC-160054

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Guo X-G, Long J-J. Cytokeratin-19 fragment in the diagnosis of bladder carcinoma. Tumor Biol. (2016) 37:14329–30. doi: 10.1007/s13277-016-5223-7

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Kuang L, Song W, Qing H, Yan S, Song F. CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis. Genet Mol Res. (2015) 14:3921–31. doi: 10.4238/2015.April.27.6

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Alavi A, Izadpanahi M-H, Haghshenas L, Faridizad R, Eslami M-J, Ghadimi K. Comparing urine levels of BLCA-4 nuclear matrix protein in patients with bladder cancer and non-bladder cancer. Int J Physiol Pathophysiol Pharmacol. (2019) 11:289–92.

PubMed Abstract | Google Scholar

33. Cai Q, Wu Y, Guo Z, Gong R, Tang Y, Yang K, et al. Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget. (2015) 6:37500. doi: 10.18632/oncotarget.6061

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Davis N, Shtabsky A, Lew S, Rona R, Leibovitch I, Nativ O, et al. A novel urine-based assay for bladder cancer diagnosis: multi-institutional validation study. Eur Urol Focus. (2018) 4:388–94. doi: 10.1016/j.euf.2016.10.004

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Nativ O, Halachmi S, Biton K, Zlotnik M, Yoffe C, Davis N, et al. PD19-09 PERFORMANCE OF A NOVEL URINE-BASED BIOMARKER FOR THE MONITORING OF BLADDER CANCER RECURRENCE. J Urol. (2017) 197:e368–82. doi: 10.1016/j.juro.2017.02.882

CrossRef Full Text | Google Scholar

36. Liang Z, Zhang Q, Wang C, Shi F, Cao H, Yu Y, et al. Hyaluronic acid/Hyaluronidase as biomarkers for bladder cancer: a diagnostic meta-analysis. Neoplasma. (2017) 64:901–8. doi: 10.4149/neo_2017_612

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Lokeshwar VB, Schroeder GL, Selzer MG, Hautmann SH, Posey JT, Duncan RC, et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid hyaluronidase and BTA-Stat tests. Cancer. (2002) 95:61–72. doi: 10.1002/cncr.10652

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Schroeder GL, Lorenzo-Gomez M-F, Hautmann SH, Friedrich MG, Ekici S, Huland H, et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol. (2004) 172:1123–6. doi: 10.1097/01.ju.0000134347.14643.ab

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Bhatt ML. Clinical utility of urinary soluble Fas in screening for bladder cancer. Asia Pac J Clin Oncol. (2016) 12:e215–21. doi: 10.1111/ajco.12165

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Yang H, Li H, Wang Z, Gao J, Guo Y. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study. Urol Int. (2013) 91:456–61. doi: 10.1159/000350752

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, et al. Soluble Fas a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer. (2006) 106:1701–7. doi: 10.1002/cncr.21795

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Kenney DM, Geschwindt RD, Kary MR, Linic JM, Sardesai NY, Li Z-Q. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary surviving. Tumor Biol. (2007) 28:57–62. doi: 10.1159/000099033

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Gontero P, Montanari E, Roupret M, Longo F, Stockley J, Kennedy A, et al. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. BJU Int. (2021) 127:198–204. doi: 10.1111/bju.15194

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Babu S, Mockler DC, Roa-Peña L, Szygalowicz A, Kim NW, Jahanfard S, et al. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia. Mod Pathol. (2019) 32:717–24. doi: 10.1038/s41379-018-0177-5

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Vasdev N, Hampson A, Agarwal S, Swamy R, Chilvers M, Hampson A, et al. The role of URO17™ biomarker to enhance diagnosis of urothelial cancer in new haematuria patients – first European data. (2020) 2:46–52. doi: 10.1002/bco2.50

CrossRef Full Text | Google Scholar

46. Babu S, Kim NW, Wu M, Chan I, Escobar-Hoyos LF, Shroyer KR. Keratin 17 is a novel cytologic biomarker for urothelial carcinoma diagnosis. Am J Clin Pathol. (2021) doi: 10.1093/ajcp/aqab050

PubMed Abstract | CrossRef Full Text | Google Scholar

47. Wolfs JRE, Hermans TJN, Koldewijn EL, van de Kerkhof D. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: a review. Urol Oncol. (2021) 39:161–70. doi: 10.1016/j.urolonc.2020.11.014

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Dudderidge T, Nabi G, Mom J, Umez-Eronini N, Hrouda D, Cresswell J, et al. A novel non-invasive aid for bladder cancer diagnosis: a prospective, multi-centre study to evaluate the ADXBLADDER test. Eur Urol Suppl. (2018) 17:31424. doi: 10.1016/S1569-9056(18)31835-9

CrossRef Full Text | Google Scholar

49. Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, et al. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. J Urol. (2017) 197:1410–8. doi: 10.1016/j.juro.2016.12.096

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Roperch J-P, Grandchamp B, Desgrandchamps F, Mongiat-Artus P, Ravery V, Ouzaid I, et al. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer. (2016) 16:1–9. doi: 10.1186/s12885-016-2748-5

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Su S-F, de Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S, et al. A panel of three markers hyper-and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. (2014) 20:1978–89. doi: 10.1158/1078-0432.CCR-13-2637

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. (2012) 109:941–8. doi: 10.1111/j.1464-410X.2011.10428.x

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Liu J, Li Y, Liao Y, Mai S, Zhang Z, Liu Z, et al. High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy. Biomed Res Int. (2013) 2013:390482. doi: 10.1155/2013/390482

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Hofbauer SL, de Martino M, Lucca I, Haitel A, Susani M, Shariat SF, et al. A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urol Oncol. (2018) 36:531.e1–8. doi: 10.1016/j.urolonc.2018.09.006

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Mengual L, Lozano JJ, Ingelmo-Torres M, Gazquez C, Ribal MJ, Alcaraz A. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer. (2013) 133:2631–41. doi: 10.1002/ijc.28274

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Sapre N, Anderson PD, Costello AJ, Hovens CM, Corcoran NM. Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise? Urol Oncol. (2014) 32:48.e9–17. doi: 10.1016/j.urolonc.2013.07.002

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Long JD, Sullivan TB, Humphrey J, Logvinenko T, Summerhayes KA, Kozinn S, et al. A non-invasive miRNA based assay to detect bladder cancer in cell-free urine. Am J Transl Res. (2015) 7:2500–9.

PubMed Abstract | Google Scholar

58. Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ, et al. A microRNA biomarker panel for the non-invasive detection of bladder cancer. Oncotarget. (2016) 7:86290–9. doi: 10.18632/oncotarget.13382

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Valenberg FJPv, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol. (2019) 75:853–60. doi: 10.1016/j.eururo.2018.11.055

PubMed Abstract | CrossRef Full Text | Google Scholar

60. van Kessel KEM, Van Neste L, Lurkin I, Zwarthoff EC, Van Criekinge W. Evaluation of an epigenetic profile for the detection of bladder cancer in patients with hematuria. J Urol. (2016) 195:601–7. doi: 10.1016/j.juro.2015.08.085

PubMed Abstract | CrossRef Full Text | Google Scholar

61. van Kessel KEM, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, et al. Validation of a DNA methylation-mutation urine assay to select patients with hematuria for cystoscopy. J Urol. (2017) 197(3 Part 1):590–5. doi: 10.1016/j.juro.2016.09.118

PubMed Abstract | CrossRef Full Text | Google Scholar

62. O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. (2012) 188:741–7. doi: 10.1016/j.juro.2012.05.003

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, et al. Performance of the Bladder EpiCheck. Methylation test for patients under surveillance for non muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur Urol Oncol. (2018) 1:307–13. doi: 10.1016/j.euo.2018.06.011

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceicao P, et al. Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study. Front Genet. (2019) 10:1237. doi: 10.3389/fgene.2019.01237

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Pena MDCR, Springer SU, Taheri D, Li L, Tregnago AC, Eich M-L, et al. Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Archiv. (2019) 476:423–9. doi: 10.1007/s00428-019-02654-1

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Bosschieter J, Lutz C, Segerink LI, Vis AN, Zwarthoff EC, van Moorselaar RJ, et al. The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. Epigenomics. (2018) 10:673–87. doi: 10.2217/epi-2017-0156

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Costa VL, Henrique R, Danielsen SA, Duarte-Pereira S, Eknaes M, Skotheim RI, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. (1557–3265 (Electronic)). 16:584–51. doi: 10.1158/1078-0432.CCR-10-1312

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Schneider AC, Heukamp LC, Rogenhofer S, Fechner G, Bastian PJ, von Ruecker A, et al. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int. (2011) 108:E290–6. doi: 10.1111/j.1464-410X.2011.10203.x

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat Rev Clin Oncol. (2011) 8:467–77. doi: 10.1038/nrclinonc.2011.76

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Chen L, Cui Z, Liu Y, Bai Y, Lan F. MicroRNAs as biomarkers for the diagnostics of bladder cancer: a meta-analysis. Clin Lab. (2015) 61:1101–8. doi: 10.7754/Clin.Lab.2015.150204

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Shi H-B, Yu J-X, Yu J-X, Feng Z, Zhang C, Li G-Y, et al. Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles. World J Surg Oncol. (2017) 15:1–10. doi: 10.1186/s12957-017-1201-9

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Yun SJ, Jeong P, Kim W-T, Kim TH, Lee Y-S, Song PH, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. (2012) 41:1871–8. doi: 10.3892/ijo.2012.1622

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Darling D, Luxmanan C, O'Sullivan P, Lough T, Suttie J. Clinical utility of cxbladder for the diagnosis of urothelial carcinoma. Adv Ther. (2017) 34:1087–96. doi: 10.1007/s12325-017-0518-7

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Lotan Y, O'Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. (2017) 35:531.e15–e22. doi: 10.1016/j.urolonc.2017.03.008

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Koya M, Osborne S, Chemaslé C, Porten S, Schuckman A, Kennedy-Smith A. An evaluation of the real world use and clinical utility of the cxbladder monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. (2020) 20:1–9. doi: 10.1186/s12894-020-0583-0

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Lough T, Luo Q, O'Sullivan P, Chemaslé C, Stotzer M, Suttie J, et al. Clinical utility of cxbladder monitor for patients with a history of urothelial carcinoma: a physician-patient real-world clinical data analysis. Oncol Ther. (2018) 6:73–85. doi: 10.1007/s40487-018-0059-5

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Nat Acad Sci. (1994) 91:9871–5. doi: 10.1073/pnas.91.21.9871

PubMed Abstract | CrossRef Full Text | Google Scholar

78. Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res. (1994) 54:2848–51.

PubMed Abstract | Google Scholar

79. Simon R, Bürger H, Brinkschmidt C, Böcker W, Hertle L, Terpe HJ. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol. (1998) 185:345–doi: 10.1002/(SICI)1096-9896(199808)185:4<345::AID-PATH109>3.0.CO;2-0

PubMed Abstract | CrossRef Full Text | Google Scholar

80. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. (1998) 58:5835–41.

PubMed Abstract | Google Scholar

81. Seripa D, Parrella P, Gallucci M, Gravina C, Papa S, Fortunato P, et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int J Cancer. (2001) 95:364–9. doi: 10.1002/1097-0215(20011120)95:6<364::AID-IJC1064>3.0.CO;2-V

PubMed Abstract | CrossRef Full Text | Google Scholar

82. van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA, et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial ). Eur Urol. (2009) 55:659–68. doi: 10.1016/j.eururo.2008.05.001

PubMed Abstract | CrossRef Full Text | Google Scholar

83. Frigerio S, Padberg BC, Strebel RT, Lenggenhager DM, Messthaler A, Abdou M-T, et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int J Cancer. (2007) 121:329–38. doi: 10.1002/ijc.22690

PubMed Abstract | CrossRef Full Text | Google Scholar

84. Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol. (2014) 192:583–92. doi: 10.1016/j.juro.2014.02.035

PubMed Abstract | CrossRef Full Text | Google Scholar

85. Liang L-G, Kong M-Q, Zhou S, Sheng Y-F, Wang P, Yu T, et al. An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. Sci Rep. (2017) 7:1–10. doi: 10.1038/srep46224

PubMed Abstract | CrossRef Full Text | Google Scholar

86. Lin S-Y, Chang C-H, Wu H-C, Lin C-C, Chang K-P, Yang C-R, et al. Proteome profiling of urinary exosomes identifies alpha 1-antitrypsin and H2B1K as diagnostic and prognostic biomarkers for urothelial carcinoma. Sci Rep. (2016) 6:1–12. doi: 10.1038/srep34446

PubMed Abstract | CrossRef Full Text | Google Scholar

87. Andreu Z, Oshiro RO, Redruello A, López-Martín S, Gutiérrez-Vázquez C, Morato E, et al. Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression. Eur J Pharm Sci. (2017) 98:70–9. doi: 10.1016/j.ejps.2016.10.008

PubMed Abstract | CrossRef Full Text | Google Scholar

88. Oeyen E, Hoekx L, Wachter SD, Baldewijns M, Ameye F, Mertens I. Bladder cancer diagnosis and follow-up: the current status and possible role of extracellular vesicles. Int J Mol Sci. (2019) 20:821. doi: 10.3390/ijms20040821

PubMed Abstract | CrossRef Full Text | Google Scholar





Plaats een reactie ...

Reageer op "Blaaskanker: Biomarkers als genmutaties (DNA) en eiwitexpressie in blaaskanker als voorspellende waarde na operatie of behandeling van niet-spierinvasieve blaaskanker zijn moeilijk te traceren. Toch zijn ze belangrijk blijkt uit overzichtstudie"


Gerelateerde artikelen
 

Gerelateerde artikelen

Enfortumab Vedotin geeft alsnog >> Blaaskanker: Immuuntherapie >>